Get the Stockscreener App
1.565
0.32%
-0.005
Boundless Bio Inc stock is traded at $1.565, with a volume of 8,030.
It is down -0.32% in the last 24 hours and up +32.63% over the past month.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.
See More
Previous Close:
$1.57
Open:
$1.54
24h Volume:
8,030
Relative Volume:
0.04
Market Cap:
$35.20M
Revenue:
-
Net Income/Loss:
$-58.20M
P/E Ratio:
-0.6012
EPS:
-2.603
Net Cash Flow:
$-47.21M
1W Performance:
+7.93%
1M Performance:
+32.63%
6M Performance:
+24.21%
1Y Performance:
-2.80%
1-Day Range:
$1.54
$1.5884
1-Week Range:
$1.43
$1.59
52-Week Range:
$0.9612
$1.7249
Boundless Bio Inc Stock (BOLD) Company Profile
Name
Boundless Bio Inc
Sector
Industry
Phone
(858) 766-9912
Address
10955 ALEXANDRIA WAY, SAN DIEGO
Compare BOLD vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BOLD
Boundless Bio Inc
|
1.57 | 35.20M | 0 | -58.20M | -47.21M | -2.603 |
VRTX
Vertex Pharmaceuticals Inc
|
428.25 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
720.03 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
811.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
304.18 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
315.00 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Boundless Bio Inc Stock (BOLD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Initiated | H.C. Wainwright | Buy |
| May-28-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-13-24 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-22-24 | Initiated | Guggenheim | Buy |
| Apr-22-24 | Initiated | Leerink Partners | Outperform |
| Apr-22-24 | Initiated | Piper Sandler | Overweight |
View All
Boundless Bio Inc Stock (BOLD) Latest News
[ARS] Boundless Bio, Inc. SEC Filing - Stock Titan
Boundless Bio (NASDAQ: BOLD) details 2026 virtual meeting and pay - Stock Titan
BOLD | Boundless Bio, Inc. Common Insider Trading - Quiver Quantitative
BOLD (Boundless Bio Inc.) falls 3.07% following wider-than-expected Q4 2025 earnings per share miss.Days To Cover - Xã Thanh Hà
OGI (Organigram Global Inc. Common Shares) delivers blowout Q1 2026 results with 62 percent annual revenue growth and positive earnings.Dividend Safety - Cổng thông tin điện tử tỉnh Lào Cai
BoundlessBio (BOLD) Stock: Technical Trend Review | Boundless Bio Inc. misses EPS estimates by 9.4% on wider lossesPEG Ratio - Cổng thông tin điện tử tỉnh Lào Cai
BoundlessBio (BOLD) Stock Top Holdings (-0.32%) 2026-04-20Hot Community Stocks - Cổng thông tin điện tử tỉnh Lào Cai
Brickell Biotech Inc (BBI) - Minichart
BoundlessBio (BOLD) Stock: Mid-Year Review (-3.07%) 2026-04-18RSI Overbought Stocks - Xã Thanh Hà
Boundless Bio Presents Preclinical Data on BBI-940, a Novel Kinesin Degrader, at AACR Annual Meeting 2026 - Quiver Quantitative
Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting - GlobeNewswire Inc.
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Tuesday's session: gap up and gap down stocks - ChartMill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Boundless Bio, Inc. Files Form 8-K with SEC – Corporate Details, Nasdaq Listing, and Emerging Growth Company Status - Minichart
Boundless Bio to terminate San Diego lease, agrees to $10 million payment - Investing.com Australia
Boundless Bio Terminates Major Long-Term San Diego Lease - TipRanks
Boundless Bio (NASDAQ: BOLD) pays $10M to exit long-term lab lease - Stock Titan
Chipmakers Recap: Is Boundless Bio Inc in a long term uptrend2026 Buyback Activity & Consistent Income Trade Ideas - baoquankhu1.vn
GODN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
EPS Watch: Is Boundless Bio Inc subject to activist investor interest2026 Volume Leaders & Safe Entry Point Alerts - baoquankhu1.vn
Aug Decliners: What hedge funds are buying Akanda Corp2026 Price Targets & Weekly High Potential Stock Alerts - baoquankhu1.vn
PMN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Swing Trade: Is EFOI forming higher highs and higher lows2026 Momentum & Weekly Momentum Stock Picks - baoquankhu1.vn
JSPR Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Is BoundlessBio (BOLD) Stock Leading the Market | Price at $1.09, Up 1.39%Technical Analysis - Cổng thông tin điện tử Tỉnh Sơn La
NVNO PE Ratio & Valuation, Is NVNO Overvalued - Intellectia AI
BOLD PE Ratio & Valuation, Is BOLD Overvalued - Intellectia AI
CUE.O PE Ratio & Valuation, Is CUE.O Overvalued - Intellectia AI
LIXT PE Ratio & Valuation, Is LIXT Overvalued - Intellectia AI
Stock List: Research Stocks from Around the World - GuruFocus
APUS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Volume Recap: Will Boundless Bio Inc face regulatory challenges2026 WrapUp & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
If You Invested $1,000 in Neuphoria Therapeutics Inc (NEUP) - Stock Titan
USA Stocks: Research Stocks from USA Stock Market - GuruFocus
What analysts say about Boundless Bio Inc stockPortfolio Gains Report & Reliable Intraday Trade Plans - baoquankhu1.vn
Checkpoint Inhibitors Competitive Landscape & Pipeline 2026: Emerging Therapies, ROA, Molecules, Companies and Future Outlook - Barchart
Checkpoint Inhibitors Competitive Landscape & Pipeline 2026: - openPR.com
Stop Loss: Can Boundless Bio Inc ride the EV wave2026 Gainers & Long Hold Capital Preservation Plans - baoquankhu1.vn
If You Invested $1,000 in Rallybio Corp (RLYB) - Stock Titan
If You Invested $1,000 in SeaStar Medical Holding Corp (ICU) - Stock Titan
BOLD Technical Analysis & Stock Price Forecast - Intellectia AI
MRKR PE Ratio & Valuation, Is MRKR Overvalued - Intellectia AI
Boundless Bio: Underestimated Biotech With First-In-Class EcDNA Targeted Kinesin Degrader - Seeking Alpha
Risks Report: Is Boundless Bio Inc stock a smart retirement pick2026 Price Momentum & Technical Confirmation Trade Alerts - baoquankhu1.vn
Boundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026 - The Manila Times
Inside a novel cancer drug aiming at ecDNA-positive, high-risk breast tumors - Stock Titan
Bear Alert: Can Boundless Bio Inc ride the EV waveInsider Buying & Weekly Momentum Picks - baoquankhu1.vn
Trend Review: Can Boundless Bio Inc maintain its current growth rateWeekly Trade Recap & Weekly High Return Stock Opportunities - baoquankhu1.vn
FORTY Should I Buy - Intellectia AI
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
Boundless Bio Inc Stock (BOLD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.78%
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):